CA15-3 and CEA tumor markers are being used to diagnose, treat, and predict breast cancer; however, as limitations such as the low efficacy and low sensitivity of early diagnosis are revealed, expectations for new tumor markers to supplement these in the future are increasing [18,19,20]. This evidence concerns the gene CEACAM5 and breast cancer.